Viral Vector Manufacturing Global Market Report 2024

The viral vector manufacturing market size has grown exponentially in recent years. It will grow from $5.82 billion in 2023 to $7 billion in 2024 at a compound annual growth rate (CAGR) of 20.4%. The growth observed during the historic period can be attributed to several factors, including the expansion of the gene therapy pipeline, notable clinical successes leading to approvals, heightened investments in biopharmaceuticals, and the rising prevalence of genetic disorders. These factors collectively contributed to the growth and advancement of viral vector manufacturing within the biopharmaceutical industry.

The viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $14.55 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The anticipated growth in the forecast period can be attributed to several factors, notably the widening applications of viral vectors in oncology, increased global collaborations within gene therapy research, the adoption of viral vectors in vaccine development, and the ongoing progress in clinical trials leading to commercialization efforts. Key trends expected in this period encompass technological innovations focused on enhancing vector production methods, the emergence of next-generation vectors with improved capabilities, efforts towards regulatory compliance and standardization within the industry, increased collaborations and partnerships among stakeholders, and the global expansion of manufacturing facilities to meet growing demands in the viral vector manufacturing landscape.

The rise in the prevalence of cancer and infectious diseases is anticipated to be a significant driver for the growth of the viral vector manufacturing market. Infectious diseases, transmitted through contact with infected individuals, animals, or objects, are caused by viruses or their toxic byproducts. Cancer, characterized by abnormal cell growth, invasion of neighboring organs, and potential spread to other parts of the body, is a diverse group of diseases. Viral vectors play a crucial role in cancer treatment by producing tumor antigens - proteins on tumor cells that trigger the body's anticancer immune response. Additionally, viral vectors have been utilized in pre-clinical and clinical trials as vaccines against various infectious diseases. According to the World Health Organization, there were 247 million cases of malaria in 2021, compared to 245 million cases in 2020. The Centers for Disease Control and Prevention reported 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US in 2020. This increase in the prevalence of cancer and infectious diseases is a key factor driving the growth of the viral vector manufacturing market.

The growth of the viral vector manufacturing market is further propelled by the expanding pipeline of gene therapy. Gene therapy involves manipulating or replacing genetic material within an individual's cells to treat or prevent diseases. Viral vector manufacturing plays a crucial role in this domain by providing efficient and scalable platforms for producing viral vectors, which serve as vital vehicles for delivering therapeutic genes into target cells. This advancement facilitates the development of innovative gene therapies. In January 2023, the American Society of Gene & Cell Therapy reported a 7% growth in the US gene, cell, and RNA therapy pipeline in 2022, totaling 3,726 therapies. The preclinical stage dominates with 70% of therapies, and oncology leads as the most active therapeutic area, hosting over 1,300 gene and cell therapy candidates. The expanding pipeline of gene therapy is a driving force behind the growth of the viral vector manufacturing market.

Product innovation is a prominent trend in the viral vector manufacturing market, with major companies introducing advanced solutions to maintain and strengthen their positions. In August 2022, Merck KGaA, a German-based science and technology company, unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. As one of the first Contract Development and Manufacturing Organizations (CDMOs) and technology creators to provide a complete viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development, Merck KGaA addresses the need for a comprehensive solution in the industry. The VirusExpress 293 AAV Production Platform allows biopharmaceutical companies to streamline process development, reduce time and costs, and accelerate the timeline for clinical manufacture.

Major players in the viral vector manufacturing market are emphasizing the development of advanced products, particularly viral vector platforms tailored for efficient viral vector production and manufacturing. Viral vector platforms are comprehensive systems designed to streamline the production and processing of viral vectors for various applications, including gene therapy and vaccine development. In May 2023, AGC Biologics, a US-based global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), launched the BravoAAV and ProntoLVV platforms. These platforms are specifically designed to provide flexible and accelerated vector development and manufacturing for cell and gene therapy programs. Offering GMP product delivery in nine months, supported by a global regulatory and supply network, and in-house plasmid DNA services, these platforms play a crucial role in meeting the increasing demand for efficient development and delivery of life-changing gene therapies and vaccines. Custom processes, templated material approaches, and prequalified analytical methods further contribute to the significance of these platforms in the viral vector manufacturing market, which is projected to reach $5.5 billion by 2035.

In January 2021, Thermo Fisher Scientific Inc., a leading US-based supplier of software, services, analytical tools, reagents and consumables, and medical equipment, completed the acquisition of Henogen S.A. for a total of $874.5 million. The strategic purpose behind this acquisition by Thermo Fisher Scientific Inc. is to enhance its global capacity for manufacturing cell and gene therapies as well as vaccines. Henogen S.A., based in Belgium, is a biomanufacturing company specializing in the production of viral vectors.

Major companies operating in the viral vector manufacturing market report are Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC,Oxford Biomedica plc, REGENXBIO Inc., LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

North America was the largest region in the viral vector manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary categories of viral vector manufacturing include adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and other variations. Adenoviral vectors, for instance, are double-stranded DNA vectors lacking an outer casing. These vectors find application across a spectrum of diseases including cancer, genetic disorders, infectious diseases, and more, utilizing workflows involving both upstream and downstream processing. These technologies have diverse applications in gene and cell therapy development, vaccine research, and the discovery phases of biopharmaceuticals and pharmaceuticals. They are extensively utilized in research institutions, biotechnology and pharmaceutical companies, and various other related fields for biomedical research purposes.

The viral vector manufacturing market research report is one of a series of new reports that provides viral vector manufacturing market statistics, including viral vector manufacturing industry global market size, regional shares, competitors with a viral vector manufacturing market share, detailed viral vector manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector manufacturing industry. This viral vector manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral vector manufacturing market includes revenues earned by entities through the production, packaging, and labeling of viral vector vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.